What Perfint Healthcare does

Perfint Healthcare is a Chennai, India-based medical device company founded in 2005 that develops and commercializes image-guided robotic positioning systems for CT-guided interventional procedures. Its two core products, MAXIO® (USFDA 510(k) cleared) and ROBIO® EX, combine 5 DOF stereotactic robotic arms with sub-millimeter accuracy, 3D visualization and multi-probe planning software, proprietary InstaReg™ fast-registration technology, and respiratory motion gating to enable precise percutaneous tumor ablation, biopsy, FNAC, drainage, and pain management procedures. The company sells directly to hospitals and academic medical centers globally, with installations confirmed across India, the United States, Russia, Vietnam, the United Kingdom, Germany, Israel, Hong Kong, China, Italy, Malaysia, Australia, Japan, and Korea.

The company's revenue model is enterprise capital-equipment sales supplemented by recurring sterile disposable consumables (end effectors, needle guides, stabilizers, drapes). Backed by Accel, Chiratae Ventures (formerly IDG Ventures India), and Norwest Venture Partners across roughly $28.6M of disclosed funding through 2016, Perfint operates a US subsidiary in Redmond, Washington, and maintains an active peer-reviewed publication and conference presence at venues such as ECIO, ECR, SIR, and RSNA. Clinical validation comes from named deployments at institutions including AIIMS Jodhpur, the Royal Marsden, NIH, Goethe University Frankfurt, the Chinese University of Hong Kong, and the University of Pisa, supporting the value proposition of reduced procedure time, lower radiation exposure, and improved reproducibility for complex percutaneous interventions.

Name

Perfint Healthcare

Legal name

Perfint Healthcare Pvt. Ltd.

Website

https://perfinthealthcare.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

251–500 employees

Short description

Perfint Healthcare develops image-guided robotic positioning systems (MAXIO® and ROBIO® EX) for CT-guided interventional oncology and pain management procedures, selling directly to hospitals and academic medical centers globally from its Chennai, India headquarters.

Ownership category

akta.pro rank

Product category

Interventional Oncology Robotics

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industry

Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)

Keywords

• Image-guided robotics
• Interventional oncology
• CT-guided ablation
• Stereotactic positioning systems
• Robotic tumor ablation

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales (Hardware + Software): Sale of robotic positioning systems (MAXIO® and ROBIO® EX) including stereotactic hardware, software platforms, and accessories. The company sells medical devices that integrate hardware and software as a combined system for interventional procedures.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Perfint Healthcare designs, manufactures and sells CT-guided robotic positioning systems (MAXIO® and ROBIO® EX) for image-guided interventional procedures in oncology and pain care. The systems combine a stereotactic robotic arm with planning and targeting software to enable sub-millimeter percutaneous needle placement, multi-probe ablation planning, and respiratory-gated targeting for tumor ablation, biopsy, drainage and pain management procedures.

Product overview

Perfint Healthcare offers two core robotic products: MAXIO® and ROBIO® EX. MAXIO® is an image-guided stereotactic accessory to CT systems that provides 3D visualization, multi-probe planning, and precise instrument placement for percutaneous procedures like tumor ablation and biopsies. ROBIO® EX is a CT & PET-CT guided robotic positioning system focused on tumor targeting and tool placement for diagnostic and therapeutic interventions. Both products are designed for image-guided interventional procedures in oncology and pain management.

Differentiator

Problem solved

Functional benefit

Brands

• MAXIO®: Image-guided, physician controlled stereotactic accessory to a Computed Tomography (CT) system for stereotactic spatial positioning and orientation during CT guided percutaneous procedures.
• ROBIO® EX

Products and services

• MAXIO® MAXIO® is an image-guided, physician-controlled stereotactic accessory to a Computed Tomography (CT) system. It provides pre-operative 3D planning with multi-probe and ablation-volume visualization, intra-operative guidance for accurate instrument placement, and post-procedure verification for CT-guided percutaneous procedures such as tumor ablation (MWA, RFA, IRE, Cryo), biopsy, FNAC and drainage.
• ROBIO® EX ROBIO® EX is a CT & PET-CT guided robotic positioning system that assists with fast and accurate tumor targeting and tool placement for abdominal and thoracic interventions, including biopsy, FNAC, pain management, drainage and tumor ablation.

Quantifiable outcome

• Sub-millimeter and sub-degree targeting accuracy
• +3 more outcomes

Named customers15 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic's Minimally Invasive Therapies group sells ablation generators (RF, MW, Cryo) and the Emprint ablation system, often used with CT guidance. Broad incumbent comparable to Perfint because Medtronic controls the ablation-energy side of the workflow that Perfint's robotics orchestrate, and competes for the same hospital capital budgets in interventional oncology.
• Siemens Healthineers: Siemens Healthineers offers CT imaging systems and the ARTIS icono interventional angiography suite, plus imaging-therapy software used to plan and verify percutaneous ablations. A broad incumbent comparable to Perfint because hospitals often procure CT, navigation software, and ablation-assist robotics as a combined interventional oncology stack, and Siemens' installed base shapes buyer expectations.
• Brainlab: Brainlab is a Munich-based digital surgery company offering image-guided surgical navigation, planning software, and intraoperative imaging across multiple specialties including neurosurgery, spine, and interventional oncology. Directly comparable to Perfint because both sell CT/image-guided planning and targeting platforms to hospitals for percutaneous and minimally invasive procedures, though Brainlab operates across a much broader surgical portfolio.
• Intuitive Surgical: Intuitive Surgical is the global leader in surgical robotics (da Vinci systems). While focused on laparoscopic robotic surgery rather than CT-guided percutaneous ablation, it is a relevant broad incumbent defining the overall surgical robotics market, capital equipment sales motion, and regulatory pathway expectations that Perfint's category must compete within.

Emerging players

• Renishaw: Renishaw's Healthcare division offers the Neuromate and Rosa surgical robots for stereotactic neurosurgical procedures, and has expanded into image-guided interventional applications. Comparable to Perfint in that both leverage precision stereotactic positioning with sub-millimeter accuracy for percutaneous image-guided interventions, though Renishaw is more diversified industrially.
• Centerline Biomedical: Centerline Biomedical (Cleveland Clinic spin-out) develops the IOPS (Intra-Operative Positioning System) for endovascular and percutaneous image-guided procedures. Emerging player comparable to Perfint because both address the same physician pain point of sub-millimeter navigation in image-guided interventions, with overlapping hospital customer profile in interventional radiology.
• Galen Robotics: Galen Robotics is developing a collaborative surgical robotic platform initially focused on ENT and laparoscopic procedures, with technology originating from Johns Hopkins. Emerging player comparable to Perfint in being a small, focused image-guided/robotic surgery company selling capital equipment into specialty hospital departments, though addressing a different surgical specialty.

Direct peers

• XACT Robotics: XACT Robotics develops the XACT ACE Robotic System, a CT-guided image-guided robotic system for percutaneous needle insertion in ablation, biopsy, and drainage procedures. Direct peer to Perfint MAXIO/ROBIO because both target interventional radiology with robotic stereotactic needle placement for oncology applications, with overlapping hospital customer profile.
• Quantum Surgical: Quantum Surgical develops the Epione robotic platform for CT-guided percutaneous tumor ablation in liver, kidney, lung, and bone. Direct peer to Perfint because both sell robotic ablation-assistance systems to interventional oncology departments, addressing percutaneous procedures with robotic guidance and software planning.
• Perfint Healthcare's Robotic Competitor: Interventional Systems (iSYS Medizintechnik): iSYS Medizintechnik (now Interventional Systems) develops the iSYS1 micro-robotic targeting system for CT- and MRI-guided percutaneous interventions including biopsy, ablation, and pain management. Direct peer to Perfint MAXIO because both sell robotic patient-mounted needle guidance systems to interventional radiology and pain management departments, with similar target procedures and customer base.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/perfint-healthcare-195909487113964
• LinkedInlinkedin.com/company/14493

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perfint Healthcare